Katia M Perez1, Kathleen L Curley2, James C Slaughter3, Ashley H Shoemaker4. 1. Wake Forest University School of Medicine, Winston-Salem, North Carolina. 2. The George Washington University School of Medicine and Health Sciences, Washington, DC. 3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Pediatrics, Division of Pediatric Endocrinology, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
Context: Pseudohypoparathyroidism (PHP) is a rare genetic disorder characterized by early-onset obesity and multihormone resistance. To treat abnormal weight gain and prevent complications such as diabetes, we must understand energy balance and glucose homeostasis in PHP types 1A and 1B. Objective: The aim of this study was to evaluate food intake, energy expenditure, and glucose homeostasis in children with PHP. Design: Assessments included resting energy expenditure (REE), physical activity, food intake, sucrose preference, questionnaires, endocrine status, and auxological status. All patients underwent an oral glucose tolerance test (OGTT). Setting: Vanderbilt University Medical Center. Patients: We assessed 16 children with PHP1A, three with PHP1B, and 15 healthy controls. Main Outcome Measures: Food intake during an ad lib buffet meal and glucose at five time points during OGTT. Results: PHP1A and control groups were well matched. Participants with PHP1A had significantly lower REE without concomitant change in food intake or physical activity. At baseline, participants with PHP1A had significantly lower fasting glucose and insulin resistance. During OGTT, participants with PHP1A had significantly delayed peak glucose and a slower rate of glucose decline despite similar oral glucose insulin sensitivity. Participants with PHP1A had 0.46% lower HbA1c levels than controls from a clinic database after adjustment for OGTT 2-hour glucose. The PHP1B group was similar to the PHP1A group. Conclusions: In contrast to other monogenic obesity syndromes, our results support reduced energy expenditure, not severe hyperphagia, as the primary cause of abnormal weight gain in PHP. Patients with PHP are at high risk for dysglycemia without reduced insulin sensitivity.
Context:Pseudohypoparathyroidism (PHP) is a rare genetic disorder characterized by early-onset obesity and multihormone resistance. To treat abnormal weight gain and prevent complications such as diabetes, we must understand energy balance and glucose homeostasis in PHP types 1A and 1B. Objective: The aim of this study was to evaluate food intake, energy expenditure, and glucose homeostasis in children with PHP. Design: Assessments included resting energy expenditure (REE), physical activity, food intake, sucrose preference, questionnaires, endocrine status, and auxological status. All patients underwent an oral glucose tolerance test (OGTT). Setting: Vanderbilt University Medical Center. Patients: We assessed 16 children with PHP1A, three with PHP1B, and 15 healthy controls. Main Outcome Measures: Food intake during an ad lib buffet meal and glucose at five time points during OGTT. Results: PHP1A and control groups were well matched. Participants with PHP1A had significantly lower REE without concomitant change in food intake or physical activity. At baseline, participants with PHP1A had significantly lower fasting glucose and insulin resistance. During OGTT, participants with PHP1A had significantly delayed peak glucose and a slower rate of glucose decline despite similar oral glucose insulin sensitivity. Participants with PHP1A had 0.46% lower HbA1c levels than controls from a clinic database after adjustment for OGTT 2-hour glucose. The PHP1B group was similar to the PHP1A group. Conclusions: In contrast to other monogenic obesity syndromes, our results support reduced energy expenditure, not severe hyperphagia, as the primary cause of abnormal weight gain in PHP. Patients with PHP are at high risk for dysglycemia without reduced insulin sensitivity.
Authors: Min Chen; Jie Wang; Kathryn E Dickerson; James Kelleher; Tao Xie; Divakar Gupta; Edwin W Lai; Karel Pacak; Oksana Gavrilova; Lee S Weinstein Journal: Cell Metab Date: 2009-06 Impact factor: 27.287
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee Journal: Cell Date: 1997-01-10 Impact factor: 41.582
Authors: I S Farooqi; G S Yeo; J M Keogh; S Aminian; S A Jebb; G Butler; T Cheetham; S O'Rahilly Journal: J Clin Invest Date: 2000-07 Impact factor: 14.808
Authors: Murat Bastepe; Leopold F Fröhlich; Geoffrey N Hendy; Olafur S Indridason; Robert G Josse; Hiroyuki Koshiyama; Jarmo Körkkö; Jon M Nakamoto; Arlan L Rosenbloom; Arnold H Slyper; Toshitsugu Sugimoto; Agathocles Tsatsoulis; John D Crawford; Harald Jüppner Journal: J Clin Invest Date: 2003-10 Impact factor: 14.808
Authors: Ozair Abawi; Emma C Koster; Mila S Welling; Sanne C M Boeters; Elisabeth F C van Rossum; Mieke M van Haelst; Bibian van der Voorn; Cornelis J de Groot; Erica L T van den Akker Journal: Front Endocrinol (Lausanne) Date: 2022-07-11 Impact factor: 6.055
Authors: Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Aurora Garcia Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen A T Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Manasori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebeca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart Journal: Horm Res Paediatr Date: 2020-08-05 Impact factor: 2.852